Publications by authors named "N Deri"

Article Synopsis
  • The study aims to compare outcomes of embryo transfer cycles using either fresh or frozen-thawed testicular sperm from non-obstructive azoospermia (NOA) patients.
  • A retrospective analysis of 48 couples involved 93 embryo transfer cycles, with similar rates of pregnancy outcomes and no significant clinical differences in birth weights or complications between both sperm groups.
  • The results indicate that neither fresh nor frozen-thawed sperm significantly affects obstetrical outcomes or neonatal birth weight, suggesting both can be used effectively.
View Article and Find Full Text PDF

Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2.

Methods: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2 dose (Sputnik V or AZD1222) and 3 dose (homologous or heterologous schedule). Neutralizing capacity was against Omicron (BA.

View Article and Find Full Text PDF
Article Synopsis
  • * Machine learning models were applied to predict confirmed disability progression after two years, achieving a ROC-AUC score of 0.71, indicating moderate accuracy, while historical disability was found to be a stronger predictor than treatment or relapse history.
  • * The research followed strict guidelines and made its coding accessible for others to facilitate future benchmarking in predicting disability progression in MS patients.
View Article and Find Full Text PDF
Article Synopsis
  • Immunosuppressive therapies like azathioprine (AZA), mycophenolate mofetil (MMF), and rituximab (RTX) are used to prevent relapses in NMOSD, but response rates specifically in Argentina were previously unknown.
  • A retrospective study analyzed 139 NMOSD patients from the RelevarEM registry, tracking their response to these treatments over a mean follow-up of 41.3 months, revealing that RTX had a significantly lower treatment failure rate compared to AZA and MMF.
  • The study found treatment failures were 42.8% for AZA, 40% for MMF, and only 10.3% for RTX, indicating that higher efficacy treatments like RTX
View Article and Find Full Text PDF